Travere Therapeutics (TVTX) – Research Analysts’ Recent Ratings Updates
Travere Therapeutics (NASDAQ: TVTX) has recently received a number of price target changes and ratings updates: 4/23/2025 – Travere Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. 4/14/2025 – Travere Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $47.00 price target on the stock. 4/11/2025 – […]
Travere Therapeutics (NASDAQ: TVTX) has recently received a number of price target changes and ratings updates: 4/23/2025 – Travere Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. 4/14/2025 – Travere Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $47.00 price target on the stock. 4/11/2025 – […]
